Exchange: OTC·Updated 03:55 PM EST

ADAPY News

News
all
press releases
Kimmtrak anchors IMCR today, but its broader T-cell receptor platform is targeting larger cancer, infectious disease and autoimmune markets.
Zacks

Advertisement|Remove ads.